BIOLINE RX 2 RSS Feed | Nachrichten - www.finanzen.net

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Mon, 24 Nov 2025 13:00:00 +0100

- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers -

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Tue, 18 Nov 2025 13:00:00 +0100

Management to Hold Conference Call at 8:30 a.m. EST

TEL AVIV, Israel,

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

Mon, 17 Nov 2025 13:00:00 +0100

Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not over-expressed (representing over 90% of cancers)

Patent ...